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ABSTRACT: Osteoporosis is the most common disease involv-
ing bone degeneration. Current clinical treatments are not able
to oﬀer a satisfying curative eﬀect, so the development of
eﬀective treatments is desired. Gene silencing through siRNA
delivery has gained great attention as a potential treatment in
bone diseases. SOST gene inhibits the Wnt signaling pathway
reducing osteoblast diﬀerentiation. Consequently, silencing
SOST genes with a speciﬁc siRNA could be a potential option
to treat osteoporosis. Generally, siRNAs have a very short half-
life and poor transfection capacity, so an eﬀective carrier is
needed. In particular, mesoporous silica nanoparticles (MSNs)
have attracted great attention for intracellular delivery of nucleic
acids. We took advantage of their high loading capacity to further load the pores with osteostatin, an osteogenic peptide.
In this study, we developed a system based on MSNs coated with poly(ethylenimine), which can eﬀectively deliver SOST
siRNA and osteostatin inside cells, with the consequent augmentation of osteogenic markers with a synergistic eﬀect. This
established the potential utility of MSNs to co-deliver both biomolecules to promote bone formation, this being a
potential alternative to treat osteoporosis.
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In the last few decades, the mean life expectancy hasincreased, which has consequently boosted the impact ofskeletal diseases. In healthy adults, bone is continuously
renewed by a coordinated process in which osteoclasts resorb
old bone and osteoblasts synthesize and mineralize new bone
matrix.1 Imbalances in this physiological process, more-
pronounced bone resorption, commonly produce a decreased
bone mass and microarchitectural deterioration of bone tissue,
named osteoporosis.2,3
The conventional treatment options of osteoporosis are
limited to (1) anti-resorptive drugs that act mainly by
suppressing osteoclast activity, preserving bone mass and
increasing bone strength; and (2) anabolic agents that induce
bone formation, eﬀectively increasing bone mass and reversing
bone deterioration.4 However, current pharmacological
therapy presents some limitations related to bioavailability
issues and toxicity.5 Thus, bisphosphonates, which are the
most clinically used anti-resorptive therapeutic drugs, are
poorly absorbed from the gastrointestinal tract.6 Consequently,
high doses are required, which leads to gastrointestinal
problems.7 Another commonly used antiresorptive drug is
Denosumab (anti-receptor activator of nuclear factor κB ligand
(RANKL) monoclonal antibody), which reduces bone
resorption by decreasing osteoclast activation and diﬀer-
entiation. As a member of the tumor necrosis factor family,
RANKL is also expressed on T lymphocytes; therefore, its
inhibition could lead to impaired immunity.8 However,
parathyroid hormone (PTH), which was the ﬁrst anabolic
agent to be approved, stimulates osteoblast function by binding
to a speciﬁc receptor and activating several signaling
pathways.9 Additionally, PTH therapy presents some dis-
advantages, such as the activation of bone resorption and the
limited eﬃcacy on nonvertebral fractures. These drawbacks
justiﬁed the research of novel analogs exhibiting “pure” bone
anabolism.10 Diﬀerent N-terminal PTH related protein
(PTHrP) peptides such as PTHrP (1−36) or PTHrP (1−
34) (abaloparatide) also bind to the PTH/PTHrP type 1
receptor as PTH. They activate the signal transduction with
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equal potency as PTH but produce less activation of bone
resorption.9 The C-terminal fragment of PTHrP (107−111)
(osteostatin) has been found to be an important osteoclast
inhibitor while inducing osteogenic features in vitro and
stimulating bone regeneration in vivo.11−14 However, the
intravenously administration of those peptides might be
impeded by proteases, opsonization, and agglutination. Our
group showed that it is possible to use bulk mesoporous
ceramics or hidroxyapatites to deliver this peptide both in vitro
and in vivo.15−17 However, if intravenous delivery might be
targeted, other vectors need to be developed. Consequently, as
it has been stated above, all of these conventional osteoporotic
drugs have a healing eﬀect far from satisfactory, and their
several side eﬀects limit their further application.
Therapies based on gene expression modiﬁcation have
merged as potential alternative treatments to bone diseases.
RNA interference is a natural cellular process that regulates
gene expression. It enables the degradation of a speciﬁc mRNA
(mRNA) and, therefore, knockdown-speciﬁc proteins.18
According to this, RNAi-based therapies, in which genes that
have been identiﬁed to down-regulate bone formation, could
be targeted leading to an alternative treatment for osteopo-
rosis.19 In this sense, gene silencing through the delivery of
small interfering RNA (siRNA) has gained great attention as a
method to increase bone formation.20−22 Wnt/β-catenin is a
major signaling pathway that regulates bone development and
remodeling.23 This pathway is inhibited by the protein
sclerostin and encoded by SOST gene. The inhibition of the
Wnt/β-catenin signaling pathway decreases bone formation by
reducing osteoblast diﬀerentiation.24−26 For this reason,
silencing SOST gene using siRNAs could be an eﬀective way
of reducing sclerostin expression and, therefore, increasing
bone formation and potentially treating osteoporosis.
Generally, siRNAs are well-known for their very short half-
life and their poor penetration capacity through cell
membranes.20,21 These unresolved issues have induced the
use of nanocarriers to protect and deliver siRNAs. Among
them, diﬀerent polymeric nanoparticles, including lip-
osomes27,28 or cationic-polymeric nanoparticles29,30 have
been proposed as siRNA nanocarriers. In this sense, poly-
(ethylenimine)-siRNA complexes have been investigated for
siRNA delivery, although their high cytotoxicity has compro-
mised their use.31
Mesoporous silica nanoparticles (MSNs) have attracted
research interest in biomedicine due to their great properties
for drug delivery, such as large surface area, high loading
capacity, and biocompatibility.32−35 It could also be high-
lighted that their surface could be chemically modiﬁed with
diﬀerent moieties to provide MSNs with diﬀerent capabilities.
Normally, surface modiﬁcations are carried out to improve the
targeting ability of nanoparticles36,37 or to design stimuli-
responsive nanocarriers.38,39 In this sense, MSNs can be
functionalized with cationic polymers such as poly-
(ethylenimine) (PEI) to transport siRNAs and achieve a
better uptake by cells.40,41 In fact, MSNs covered with PEI
have been reported to be biocompatible, showing much less
Figure 1. Schematic representation of the designed nanocarrier based on mesoporous silica nanoparticles loaded with osteostatin and siRNA
to knockdown SOST and promote the expression of early markers of osteogenic diﬀerentiation both in vitro and in vivo.
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cytotoxicity to cells than the PEI-siRNA complexes mentioned
above.40
In this work, we have engineered a system based on MSNs
coated with PEI that can eﬀectively bind and deliver SOST
siRNA, preserving its knockdown capability and increasing
bone formation (Figure 1). We took advantage of the high
loading capacity of MSNs to further loading the pores with
osteostatin, which has been observed to stimulate osteoblastic
cell growth and diﬀerentiation.42 Thus, this dual therapy is
expected to boost bone formation being a potential alternative
to the current treatments for osteoporosis.
RESULTS AND DISCUSSION
MSNs@PEI and Eﬀective Loading and Delivering of
SOST siRNA inside Cells. Mesoporous silica nanoparticles
with diameter of ca. 150 nm and mesopores of 2 nm were
synthesized following a modiﬁcation of the Stöber method.43
(See the Methods section for details of MSNs synthesis,
functionalization, and characterization.) The external surface of
the nanoparticles was functionalized with phosphonate groups,
providing the strong negative charge to the nanoparticles
surface needed to coat them afterwards with the cationic
polymer. The PEI grafting to MSNs surface was veriﬁed by
diﬀerent characterization techniques as it is described below.
The PEI coating was conﬁrmed through the phosphotungstic
acid stained-layer covering the surface of PEI functionalized
nanoparticles, which was not present on the plain as it can be
appreciated by transmission electron microscopy (TEM).
TEM also showed that the nanoparticles were spherical and
monodispersed (Figure 2A).
MSNs presented the characteristic zeta potential of −21.5
mV at pH = 7, which was shifted to positive and 31 mV at pH
= 7 after PEI coating (Figure 2B). These data conﬁrm that the
external surface of the particles was successfully grafted with
the polymer (more details of the characterization can be found
in the Supporting Information).
The aim of covering the surface of MSNs with PEI was to
provide them with the ability to bind siRNA. However,
depending on the molecular weight employed, PEI could
damage the cell membrane, mitochondria, and lysosomes.44,45
Therefore, optimization of PEI coating was the ﬁrst task to
accomplish in this work using diﬀerent molecular weights (5, 8,
and 10 kDa). Their capacity of binding to siRNA versus
reduction of toxicity was evaluated using a ﬂuorescent siRNA-
analog (siGLO Green Transfection Indicator).
In vitro cell viability of MSNs coated with PEI (MSNs@PEI)
was evaluated by incubating the nanoparticles at diﬀerent
concentrations with mouse embryonic ﬁbroblast (MEF) cells
for 2 h. Then, the cell viability was measured after 48 h of
incubation, and it was found that MSNs@PEI of 10 kDa
reduced the cellular viability at concentrations >100 μg/mL
(Figure 3A). In contrast, nanoparticles coated with 8 or 5 kDa
PEI showed no toxic eﬀects at concentrations as high as 200
μg/mL. It should be noted that bare nanoparticles without PEI
coating were nontoxic for MEF cells at concentrations as high
as 200 μg/mL. Therefore, MSNs@PEI of 10 kDa were refused
due to their toxicity, and we focused on MSNs@PEI of 5 kDa.
The siRNA delivery from MSNs@PEI was initially
determined by the binding capacity of the polymeric coating
towards the nucleic acid. The highest amount of siRNA that
could be bound to MSNs@PEI was determined by agarose gel
electrophoresis. In particular, diﬀerent amounts of MSNs@PEI
ranging from 0.8 to 6.4 μg (using PEI with diﬀerent molecular
weights) were dispersed with 0.1 μg of siRNA in aqueous
solution to obtain particle-to-nucleic acid ratios (N/P) of 8−
64. N/P is a mass ratio in which N and P, respectively,
correspond to the mass of positive (nitrogen (MSNs@PEI))
and negative (phosphonate (siGLO)) charges (Figure 3B).
The ratio results from dividing the μg of nanoparticles between
the μg of siRNA. One channel was ﬁlled just with siGLO as
control (ϕ). Then, these dispersions with diﬀerent nano-
particle to siRNA (N/P) ratios were electrophoresed. Only
uncomplexed siGLO was able to migrate to the positive
electrode and, therefore, be observed on the gel. Thus, when
the band generated by siGLO is no longer visible means that
all the nucleic acid has been complexed with the added
nanoparticles, and that would be the optimal concentration of
nanoparticles needed to complex the siGLO present. The
results observed in Figure 3b indicated that all siGLO was
bound to the nanoparticles at a N/P ratio of >16 (for PEI 5
kDa) and >32 (for PEI 8 and 10 kDa). Thus, 16 μg of MSNs@
PEI 5 kDa were needed to load 1 μg of siGLO and 32 μg of the
MSNs@PEI 8 and 10 kDa. Consequently, the siRNA loading
capacity of the nanoparticles was found to be ca. 5 wt %.
Taking into consideration that the amount of siRNA
recommended by the manufacturer to achieve a proper
Figure 2. PEI grafting to MSNs surface. TEM micrographs of the nanoparticles (A) before and (B) after coating with 5 kDa PEI polymer.
The ζ potential before and after coating with 5, 8, and 10 kDa PEI polymer (bottom right corner inset).
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knockdown eﬀect was around 0.5−1 μM, it means that ﬁnal
concentration should be between 6.65 and 13.3 μg/mL. Thus,
taking into account the ratio obtained (16 N/P ratio), we can
aproximate that the nanoparticle concentration should be
between 106 and 213 μg/mL, which is within the nontoxicity
window for 5 kDa PEI. Then, although the loading capacity of
the nanoparticles could be considered low, it was found to be
good enough to transport the eﬃcient amount of siRNA
needed for an eﬀective knockdown.
Consequently, the 5 kDa PEI resulted on the lowest cell
toxicity of MSNs@PEI while maintaining the eﬀective siRNA
bind and delivery ability. Based on these results, the 5 kDa PEI
was selected and further used for the next steps in our research.
It is worth mentioning that the siRNA presence in the PEI
mesh remained the cell viability unchanged (Figure S2).
The next step consisted on the evaluation of the cellular
uptake of the MSNs@PEI through ﬂow cytometry (Figure 4A)
and confocal laser scanning microscopy (Figures 4B and 5).
For the ﬂow cytometry assay, FITC labeled nanoparticles (F-
MSNs) coated with PEI and bound with siGLO were used.
After coating the MSNs with PEI, the nanoparticle uptake
signiﬁcantly increased, which could be ascribed to the drastic
change on the surface charge previously mentioned, from
negative (MSNs) to positive (MSNs@PEI). This is in
agreement with the literature because it is easier for the
surface membrane (negative) to endocyte the positively
charged nanoparticles (Figure 4A).44 After the binding of the
siGLO to the nanoparticles, the amount of nanoparticles
internalized was approximately the same as expected, but the
ﬂuorescence intensity doubled, conﬁrming that siGLO was
inside the cells being the responsible of the ﬂuorescence
intensity increase.
For the microscopy assay, rhodamine B-labeled nano-
particles coated with PEI and bound with siGLO were used.
The MSNs (red) and siGLO (green) co-localize in the cell
(yellow), proving that the nucleic acid was attached to the PEI
mesh at the initial stage of the experiment (Figure 4B).
The Rh-MSNs@PEI-siGLO were added to the cells and
after 2 h, the media, including the non-internalized nano-
particles, were removed and refreshed. At that moment (0 h),
green and red ﬂuorescence co-localize, while after 48 h, the
green ﬂuorescence started to spread, turning green the
cytoplasm, which could be ascribed to the siGLO being
released from the Rh-MSNs@PEI (Figure 5).
The release kinetics of the MSN@PEI carrier was evaluated
using siGLO as a siRNA model. Loaded nanoparticles were
suspended in phosphate-buﬀered saline (PBS) and placed on a
Transwell permeable support. At every time point studied, the
amount of cargo released in the solution outside the transwell
was determined by ﬂuorescence. Figure S3 shows the release
proﬁle of siGLO from MSNs@PEI. At the beginning, only a
small amount of the cargo was released (around 20% of the
cargo after 24 h), possibly due to the strong interactions
between PEI and siRNA.30 However, over 80% of the cargo
was released after 48 h as a consequence of the reduction of
the electrostatic interaction between siGLO and the cationic
mesh. This release delay would provide the system with the
necessary time to arrive to the target area (osteoporotic bone)
before releasing the cargo, providing the protection that siRNA
needs around system circulation.
In Vitro Model for SOST Expression. To demonstrate
that the designed system could eﬀectively knockdown the
SOST gene in vitro, it was necessary to have a cell line that
expressed this gene. In particular, it has been reported that
MEFs generate detectable levels of SOST expression.28 Thus,
we cultured MEFs for 3 weeks observing increased levels of
SOST expression detectable after 3 days, which were increased
up to 20-fold after 14 days (Figure 6A). It was also observed
that as SOST mRNA levels lessened, the expression of two
osteoblastic diﬀerentiation markers, Runx2 and Alp, increased
(Figures 6B,C).
As mentioned above, SOST gene is involved in diﬀerent
developmental processes, particularly, inhibits osteoblastic
activity and diﬀerentiation, therefore modulates bone for-
mation. Then, when cells diﬀerentiate, SOST expression falls
and decreases to lower values, instead, diﬀerent genes like
Runx2 or Alp, known as osteogenic markers, increased their
expression. The results obtained by real-time PCR are in
agreement with this statement.
In consequence, MEFs provides an in vitro system in which
SOST is greatly expressed after 2 weeks of incubation without
the necessity to expose the cells to any osteogenic inductors.
This system would permit us to study the SOST knockdown
eﬃciency by the speciﬁc siRNA. In addition, the modiﬁed
expression of osteogenic markers as well as SOST gene in MEF
cells permits its use to evaluate the impact of SOST
knockdown on bone osteogenic marker genes.
Silencing Capability of MSNs@PEI-siRNA. First, it was
necessary to evaluate the free SiRNA capacity to in vitro
knockdown SOST gene in MEF model. The transfection of
Figure 3. Eﬀective SOST siRNA model molecule binding to
MSNs@PEI and cell viability in mouse embryonic ﬁbroblast
(MEF) cells. (A) MEF cell viability (measured by Alamar Blue) in
contact with diﬀerent concentrations of MSNs@PEI nanoparticles
at 48 h of cell culture. Data are mean ± SEM of three independent
experiments performed in triplicate. Pound signs indicate p < 0.01
vs MSN, MSNs@PEI 5kD, and MSNs@PEI 8kD. (B) Agarose gel
electrophoresis of MSNs@PEI and complexed siGLO siRNA in
diﬀerent nanoparticle to nucleic acid (N/P) ratios. M: molecular
weight marker. The ϕ lane contains only siRNA. After the loading
of osteostatin, the N/P ratio and the electrophoretic mobility did
not change. The data showed that all siRNA was bound when the
N-to-P ratio was over 16 in MSNs@PEI 5 kDa, and over 32 in the
case of PEI 8 kDa and PEI 10 kDa.
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SOST siRNA to MEF cells was evaluated after 14 days of
incubation in Dulbecco’s modiﬁed Eagle medium (DMEM).
That period of time was selected after the previous experiment,
in which the maximum expression of SOST in MEF cells was
observed after 14 days of culture. SiRNA transfection was
promoted using Accell siRNA delivery media (free from BSA,
which inhibit the transfection of free Accell siRNA).
Quantitative reverse transcription polymerase chain reaction
(qRT-PCR) was used to evaluate SOST expression after 2 h of
transfection at day 14 of cell culture. A pair of controls were
used to optimize the experiment: a negative control siRNA
(SiCtl) (“non-targeting control”, which targets a site that is
absent in human, mouse, and rat genomes), as well as positive
control (PosControl) (“GAPD control”, which targets
GAPDH, a gene common between human, mouse, and rat).
SiCtl is necessary to verify that the silencing resulted from a
sequence-speciﬁc process, and it is not due to a nonspeciﬁc
eﬀect. In contrast, PosControl targets a housekeeping gene,
which means that the target gene is expressed in all cell types at
a level that does not ﬂuctuate with cell cycle. In this sense,
PosControl would verify the eﬃciency of siRNA delivery into
cells. It was also used an untreated control (MEF or MSNs@
PEI MEF) to determine a baseline of target gene level. After
evaluation of the gene expression levels (Figure S4), it was
found that when treating the cells with the SiCtl, SOST
expression was very similar to the untreated control (MEF).
Instead, after applying the PosControl, SOST expression
decreased to signiﬁcantly lower levels, conﬁrming that siRNA
transfection was carried out successfully. The data obtained
showed that the expression of SOST decreased notably (ca.
98%) after treatment with SOST siRNA, verifying its
functionality and the utility of the in vitro model to assess
afterwards the capability of MSNs@PEI to transfect siRNA
into cells.
After conﬁrming the siRNA activity, we have to take into
account that in a real in vivo scenario, siRNA cannot just be
injected into the bloodstream because it would be degraded, so
a nanocarrier was designed for delivering the siRNA. It was
necessary to verify that siRNA knockdown capability was
maintained after being bound and released from MSNs@PEI.
The eﬃcacy of SOST siRNA delivered by MSNs@PEI was
evaluated in MEFs. In this case, the MSNs would be the
transfection vector, and then it was not necessary to use the
Accell siRNA delivery media; hence, DMEM was used instead.
At day 14 of culture, 600 μL of a 115 μg/mL MSNs@PEI
dispersion bound with 15 μL of 20 μM siRNA were added to
the cells, and after 2 h, the media were refreshed. Considering
the amount of siRNA bound to the nanoparticles as well as the
nanoparticles internalized inside the cells, we could approx-
imate the amount of siRNA delivered to the cells, assuming
that all the siRNA loaded would be released. A total of 600 μL
of a 115 μg/mL MSNs@PEI dispersion bound with 15 μL of
Figure 4. MSNs@PEI-siGLO uptake by mouse embryonic ﬁbroblast (MEF) cells by ﬂow cytometry and ﬂuorescence microscopy. (A)
Cellular uptake of diﬀerent ﬂuorescein-labeled MSNs, MSNs@PEI, and MSNs@PEI-siGLO was measured by ﬂow cytometry at 2 h of
internalization in MEF cells. Representative ﬂow cytometry images are shown on the top. Data are mean ± SEM of three independent
experiments performed in triplicate. Asterisks indicate p < 0.03 vs MSN; pound signs indicate p < 0.01 vs MSN and MSNs@PEI. (B)
Representative confocal laser scanning microscopy images of MEF cells incubated with Rhodamine-B-labeled MSNs, MSNs@PEI, and
MSNs@PEI-siGLO nanoparticles at 2 h of internalization. Blue ﬂuorescence (nuclei), red ﬂuorescence (Rh-MSNs@PEI), and green
ﬂuorescence (siGLO).
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Figure 5. SiGLO release from MSNs@PEI in MEF cells. Representative ﬂuorescence microscopy images of MEF cells incubated 2 h with
MSNs@PEI nanoparticles with siGLO at 0 and 48 h after nanoparticle incubation. Blue ﬂuorescence (nuclei), red ﬂuorescence (MSNs@
PEI), and green ﬂuorescence (siGLO). Arrows denote the siGLO released.
Figure 6. Changes in SOST mRNA levels and Runx2 and Alp bone osteogenic markers in MEF cells. (A) SOST, (B) Alp, and (C) Runx2
gene expression (measured by real-time PCR) in MEF cells at diﬀerent times. Data are mean ± SEM of three independent experiments
performed in triplicate. Single asterisks indicate p < 0.01 vs 3 days; triple asterisks indicate p < 0.001 vs 3 and 7 days.
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20 μM of siRNA was added to cells, i.e. 70 μg of nanoparticles
were loaded with 4 μg of siRNA. The 80% of the loaded
nanocarriers were internalized, which means that, 56 μg of
nanoparticles were taken up, and 3.2 μg of siRNA were
released into cells.
Then, after 48 h, SOST-mRNA was measured using qRT-
PCR. MEFs transfected with SOST siRNA presented a
signiﬁcant reduced expression of SOST relative to NeControl
(ca. 95%) as well as MSNs@PEI control (Figure 7A), which
was quite similar to the one obtained before with the Accell
siRNA transfected with the Accell siRNA delivery media.
Osteogenic markers gene levels (Runx2 and Alp) were also
measured to determine the impact of SOST down-regulation
(Figure 7B,C). Because SOST is a gene involved in cell-
diﬀerentiation inhibition, its knockdown is expected to increase
the expression of these osteogenic markers. The data showed,
as it was proposed above, that when SOST was knocked down,
the expression of the osteogenic markers increased, being
correlated with a possibly increased cell diﬀerentiation in a
complex environment such as osteopororotic bone. The
expression of Runx2 increased up to 2-fold and Alp up to
1.5-fold after siRNA transfection compare to MEF cells
expression (Figure 7B,C). The increment in bone osteogenic
markers expression was slight; thus, the next step was to
evaluate the coadministration with other anabolic agent to
determine if an additive eﬀect could be achieved.
Co-delivery of siRNA and Osteostatin to Cells and Its
Eﬀect in Osteogenic Marker Expression. Even though
osteostatin has been shown to be eﬀective at inducing
osteoblast diﬀerentiation in vitro (even in the sub-nanometer
range)11−14 and increasing bone regeneration in vivo,15−17 its
use in combination with siRNAs has never been reported. As it
has been mentioned above, MSNs could be used to explore
that possible synergistic eﬀect. For this reason, we designed a
dual release system in which osteostatin would be loaded in the
mesopores, and the therapeutic siRNA would be bound to the
PEI network. In this sense, the system will be able to transport
and release both molecules at the target destination, where the
eﬀect of their dual release would be evaluated.
First, it was necessary to test whether the PEI coating aﬀects
the osteostatin release from the MSNs. Osteostatin was loaded
in the mesopores of the MSNs by immersing the nanoparticles
in a solution of osteostatin overnight, and then the nano-
particles were coated with PEI. Afterwards, a release experi-
ment was carried out, and the amount of osteostatin released
was measured by ﬂuorescence (Figure 8). Osteostatin release
data showed in Figure 8 can be ﬁtted to a ﬁrst-order kinetic
model, with a typical release proﬁle from mesoporous materials
(eq 1):39
= − −Y A(1 e )kt (1)
Figure 7. SOST, Runx2, and ALP gene expression in the presence of SiRNA-Sost bound to MSNs@PEI in MEF cells. (A) SOST mRNA
expression (measured by real-time PCR) in MEF cells at 14 days of cell culture. (B) Alp and (C) Runx2 mRNA expression (measured by
real-time PCR) in MEF cells at 14 days of cell culture. A negative-control siRNA (SiCtl) was used. MSNs@PEI nanoparticles bound to
NeControl (MSNs@PEI SiCtl). Data are mean ± SEM of three independent experiments performed in triplicate. Asterisks indicate p < 0.01
vs MSNs@PEI MEF control cells.
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The equation parameters could be described as Y being the
amount of osteostatin released (microgram of osteostatin per
milligram of MSNs@PEI) at time t (h), with A being the
maximum amount of osteostatin released (in micrograms of
osteostatin per milligram of MSNs@PEI), and with k being the
release rate constant. The release data showed that MSNs
loaded with osteostatin and coated with PEI (OST-MSNs@
PEI) released osteostatin in a time-dependent manner,
reaching values of 0.5476 micrograms of osteostatin per
milligram of MSNs@PEI. Thus, despite PEI coating, which it
is not acting as a physical barrier impeding the osteostatin
release, the MSNs were able to release the cargo, so MSNs@
PEI could be used to transport and deliver osteostatin.
Osteostatin delivery from other mesoporous matrices, such as
SBA15, has been previously explored in vivo, conferring
osteoinductive features thanks to the peptide delivery. In
fact, despite the non-controlled delivery of osteostatin, no
clinical alterations were observed.15
After testing of the osteostatin and siRNA release separately,
both components were integrated into a multifunctional
system capable of release both biomolecules inside cells.
Figure 8. Time-dependent osteostatin (OST) release from MSNs@
PEI in PBS at pH 7.4, simulating the physiological ﬂuids.
Nanoparticles were loaded with OST and afterwards coated with
PEI (OST-MSNs@PEI). Points to trace the curves are the means
of three independent measurements per time period.
Figure 9. (A) SOST, (B) Alp, and (C) Runx2bone osteogenic markers gene expression in the presence of SiRNA-SOST bound to MSNs@
PEI in mouse embryonic ﬁbroblast (MEF) cells in the presence or absence of osteostatin (OST). SOST mRNA expression (measured by
real-time PCR) in MEF cells at 14 days of cell culture and Alp and Runx2 mRNA expression (measured by real-time PCR) in MEF cells at 14
days of cell culture. To optimize the experiment, one control was used: a negative control siRNA (SiCtl) (“non-targeting control”, which
targets a site that is absent in human, mouse, and rat genomes); MSNs@PEI nanoparticles were bound to SiCtl (MSNs@PEI SiCtl). Data are
mean ± SEM of three independent experiments performed in triplicate. Triple asterisks indicate p < 0.001 vs MSNs@PEI MEF; pound signs
indicate p < 0.05 vs OST-MSNs@PEI and MSNs@PEI-SiRNA.
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First, osteostatin was loaded into the mesopores as described
above. Then, the PEI coating was accomplished, and siRNA
was bound, leading to the ﬁnal system (OST-MSNs@PEI-
siRNA). At day 14 of MEF cell culturing, the complete system
was added to the cells following the same procedure described
above. After 48 h, SOST-mRNA, Runx2 and Alp expression
were measured (Figure 9). The results showed that SOST was
eﬀectively knocked down either by the SOST-siRNA release or
the osteostatin release and, more eﬃciently, by the delivery of
both molecules (Figure 9A). Furthermore, Alp expression rose
up to 17-fold when OST-MSNs@PEI-siRNA were adminis-
trated (Figure 9B). Besides, Runx2 expression notably
increased up to 110-fold when osteostatin and SOST siRNA
were released together by the nanoparticles (Figure 9C). The
results obtained with the administration of the nanocarrier
loaded just with SOST siRNA (MSNs@PEI-siRNA) or only
with osteostatin (OST-MSNs@PEI) were also measured and
compared with those obtained with the nanocarrier loaded
with both. The data showed that the coadministration of both
biomolecules at the same time, compared with the
administration of the biomolecules separately, increased the
expression of both osteogenic markers to notably high levels,
being a combined eﬀect between osteostatin and siRNA. It was
also measured the eﬀect of one pulse of free osteostatin at the
same concentration as the one achieved by the nanoparticles
(7 × 10−7 M). It is true that in both cases (Runx2 and Alp),
the gene expression levels rose up signaly higher when the
osteostatin is released from the nanoparticles than when is
added on its free form. This fact has been noticed before,
producing higher eﬀects in mineralization the continuous
release of free osteostatin from a mesoporous biomaterial than
one pulse of osteostatin at the beginning of the experiment.17
The reasons that could support this theory are, ﬁrst, that from
the osteogenic perspective, a controlled and sustained released
of osteostatin for longer time is more eﬀective than a punctual
administration of higher doses of osteostatin. Second, it has
also been reported that, the mere presence of silica would
increase the expression of diﬀerent osteogenic markers as well
as increase the proliferation of osteoblast.46 In addition, the
MSNs could also protect the peptide from degradation, being
gradually released in perfect conditions. So, unlike just one
pulse of osteostatin at the beginning of the experiment, which
would be progressively degraded, the release from MSNs
would keep a uniform concentration of active osteostatin for
Figure 10. In vivo injection of OST-MSNs@PEI-siRNA. SOST, Alp, and Runx2 bone osteogenic markers gene expression in the presence of
SiRNA-SOST bound to MSNs@PEI in ovariectomized mice (OVX) in the presence or absence of osteostatin. (A) Femur bone-marrow
injection in ovariectomized female mice and cyanine-7 labeled nanoparticles accumulation. (B) SOST mRNA expression (measured by real-
time PCR) in femur bone. (C) Alp and (D) Runx2 mRNA expression (measured by real-time PCR) in femur bone. To optimize the
experiment, one control was used: a negative control siRNA (SiCtl) (“non-targeting control”, which targets an absent site in human, mouse,
and rat genomes) and MSNs@PEI nanoparticles bound to SiCtl (MSNs@PEI SiCtl). Data are mean ± SEM of three independent
experiments performed in triplicate. Triple asterisks indicate p < 0.001 vs MSNs@PEI; pound signs indicate p < 0.05 vs OST-MSNs@PEI
and MSNs@PEI-SiRNA.
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longer time, being that the eﬀect in this sense is more
noticeable. Therefore, the delivery of osteostatin from our
system improves osteostatin eﬀects in osteogenic marker
expression.
In Vivo Evaluation of siRNA and OST Co-delivery and
Their Implications on Gene Expression. After the
successful in vitro validation of the system, the next step was
the in vivo evaluation in a reduced bone mass model. It has
been used ovariectomized C57/BL6 female mice with a
decreased femoral bone mineral density compared to non-
ovariectomized (62.98 ± 0.28 mg/cm2 versus 66.56 ± 0.47
mg/cm2; p < 0.001) as previously described.47 First, 50 μL of
the complete nanocarrier (OST-MSNs@PEI-siRNA) disper-
sion (0.8 mg/mL) were injected in the femur bone marrow of
ovariectomized mice (Figure 10A). Even-higher concentrations
of these nanoparticles have been widely used in diﬀerent works
without any toxic eﬀects.39,48−50 After 5 days, SOST, Runx2,
and Alp mRNA were measured by qRT-PCR (Figure 10).
Because the injection of the nanoparticles was local, i.e., the
nanoparticles were already at the target tissue, we did not
evaluate the biodistribution of the nanoparticles in the animals.
First, it should be mentioned that, the expression of SOST in
ovariectomized mice (OVX) increased compared to non-
ovariectomized mice (control) and were statistically signiﬁcant.
However, the injection of the nanoparticles, with SOST siRNA
or osteostatin notably decreased the expression of SOST (ca.
50% and 60%, respectively), being particularly eﬀective the
injection of the SOST siRNA and osteostatin coloaded
nanoparticles, which achieved the greatest knockdown eﬀect,
ca. 75% of silencing (Figure 10B).
The osteogenic markers, Runx2 and Alp, decreased their
expression in OVX compared to Control group as expected
(Figure 10C,D). The results also showed that Runx2 and Alp
expression notably increased when osteostatin and SOST
siRNA were released together by the complete system (up to 3
or 2.2 n-fold, respectively, compared with OVX), in total
agreement with the previously in vitro results. The results
obtained with the administration of the system loaded just with
the SOST siRNA (OVX+MSNs-siRNA) or only with the
osteostatin (OVX+MSNs-OST) were also measured, being up
to 1.5 or 2.5 n-fold, respectively, for Runx2 and up to 1.8 or 2.6
n-fold, respectively, for Alp, compared with OVX. The data
showed that the co-administration of both biomolecules at the
same time compared with the administration of the
biomolecules separately, increased the expression of both
osteogenic markers to notably higher levels and decreased the
expression of SOST gene, being a combined eﬀect between
osteostatin and siRNA (OVX plus MSNs-siRNA plus OST).
The design of the dual delivery nanosystem enhanced the
expression of osteogenic markers and, eﬀectively, knockdown
of the SOST gene through the combined eﬀect of osteostatin
and SOST siRNA in vivo, being a synergy between this two
molecules. This complete system could provide a potential
alternative to the current treatment of osteoporosis, empower-
ing cell diﬀerentiation by osteogenic features.
CONCLUSIONS
The inhibition of the Wnt/β-catenin pathway has recently
gained attention as therapeutic target in bone diseases such as
osteoporosis. One of the main inhibitors of this pathway is
sclerostin, a protein encoded by the SOST gene. Its activity
results in a reduction of osteoblast formation and diﬀer-
entiation. Several types of sclerostin monoclonal antibodies
have been developed as anabolic drugs to block the activity of
sclerostin, increasing osteoblast diﬀerentiation for osteoporosis
treatment.5,9,51−53 However, these antibodies can cause an
immune response, which limits the use of this treatment.53
Silencing SOST gene with a speciﬁc siRNA in osteocytes could
be a more eﬀective approach that could overcome the immune
response limitation. Osteocytes are the most abundant cells in
bone tissue and responsible for SOST gene expression. In face
of the diﬃculties with ﬁnding an osteocyte in vitro model that
expresses SOST; we had to use MEFs, which are known to
generate detectable levels of SOST expression. We optimized
the conditions of MEFs culturing so we could use them as a
platform to test the siRNA eﬀectivity. Even though siRNAs
seem to be promising candidates as therapy agents for bone
disorders, their main problem relies on their delivery due to
their very short half-life and poor internalization capacity
through cell membranes. This is an old problem for nucleic
acid therapeutics, in which the major challenge has remained
the same for the last 40 years.54 Here, we have employed
MSNs as siRNA nanocarriers due to their exquisite properties
for drug delivery, such as large surface area, high loading
capacity, and biocompatibility, among others. We took
advantage of the network of cavities within of MSNs to load
the pores with the osteogenic peptide osteostatin, which has
been observed to stimulate osteoblastic cell growth and
diﬀerentiation.
Hence, our purpose was to co-deliver two therapeutic
agents, SOST siRNA and osteostatin, at the same time inside
cells. After evaluation of the eﬀect of both biomolecules in vitro
with promising results (high capacity of silencing SOST and
notably higher levels of the osteogenic markers), the system
was injected in the femoral bone marrow of ovariectomized
mice, and the obtained results were in agreement with the in
vitro experiments. However, mice treated with each bio-
molecule separately have modiﬁed the expression of the three
genes, (knocking down SOST and increasing the expression of
Runx2 and Alp), the co-administration of both biomolecules
yielded synergistic eﬀects. Thus, it can be concluded that our
system was able to transport, co-deliver, and transfect to cells
SOST siRNA and osteostatin, maintaining its activity and
achieving an eﬀective silencing eﬀect. The combination of
SOST siRNA with the osteogenic peptide, promoted a
synergistic eﬀect, thus increasing the expression of early
markers of osteogenic diﬀerentiation in ovariectomized mice.
These promising results might lead to further investigations.
This system has demonstrated remarkable eﬃcacy for an
intrabone marrow injection. In consequence, this system will
constitute a promising candidate as a platform for gene therapy
in osteoporosis treatment.
METHODS
Synthesis and Surface Modiﬁcation of Mesoporous Silica
Nanoparticles. Mesoporous silica nanoparticles, MSNs, were
synthesized following a modiﬁcation of the Stöber method.43 First,
cetyltrimethylammonium bromide (CTAB (1 g, 2.74 mmol)), the
structure directing agent, was dissolved in H2O (480 mL) and NaOH
(3.5 mL, 2 M) in a 1 L round-bottom ﬂask under moderate magnetic
stirring. The mixture was heated at 80 °C, and tetraethylorthosilicate
(TEOS (4.5 mL, 20.15 mmol)) was added drop-wise at 0.33 mL/min
rate with a pump. For the phosphonate modiﬁcation, 30 min after the
TEOS addition, 3-trihydroxysilylpropyl methylphosphonate (TSPMP
(0.5 mL, 1.31 mmol)) was added and heated for a further 1.5 h at 80
°C under magnetic stirring. Then, the solution was centrifuged and
washed once with water and twice with ethanol. The product was
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dried at room temperature under vacuum. The surfactant was
removed by ionic exchange using 350 mL of a solution of ammonium
nitrate (10 mg/mL) in ethanol (95%) at 80 °C overnight under
magnetic stirring. The product was centrifuged, washed 3 times with
ethanol, and dried under vacuum.
Rhodamine B-labeled nanoparticles and ﬂuorescein isothiocyanate
(FITC)-labeled nanoparticles were synthesized by reacting 1 mg of
Rhodamine-B isothiocyanate or ﬂuorescein isothiocyanate with 2.2 μL
of (3-aminopropyl)triethoxysilane (APTES) in 100 μL of ethanol for
2 h. Then, this solution was mixed with 4.5 mL of TEOS, and the
whole mixture was added to the surfactant solution as previously
described. The rest of the procedure was carried out as described
above.
For the synthesis of cyanine-7-labeled nanoparticles, 5 mg of
cyanine-7 with 4.4 μL of APTES were dissolved in 140 μL of dimethyl
sulfoxide and stirred overnight. Then, this solution was mixed with 4.5
mL of TEOS, and the whole mixture was added to the surfactant
solution as previously described. The rest of the procedure was carried
out as described above.
To perform the PEI coating, 5 mg of phosphonate-modiﬁed
nanoparticles were dispersed in a solution of 2.5 mg of PEI (5, 8, and
10 kDa) in 1 mL of absolute ethanol. After sonicating for 20 s and
stirring for 30 min, the PEI coated nanoparticles (MSNs@PEI) were
consequently washed with PBS and ethanol.41
Physicochemical Characterization of MSNs. All of the
materials were characterized for size, shape, and charge. Surface
morphology was analyzed by transmission electron microscopy
(TEM) carried out with a JEOL JEM 2100 instrument operated at
200 kV, equipped with a charge-coupled device camera (KeenView
Camera). The ζ potential and hydrodynamic size of nanoparticles
were measured by means of a Zetasizer Nano ZS (Malvern
Instruments) equipped with a 633 nm “red” laser. The PEI coating
was veriﬁed by thermogravimetry and Fourier-transform infrared
(FTIR) spectra. Thermogravimetry and diﬀerential temperature
analyses (TGA/DTA) were performed in a PerkinElmer Pyris
Diamond TG/DTA analyzer, with 5 °C/min heating ramping up
from room temperature to 600 °C. A Nicolet Nexus spectrometer
(Thermo Fisher Scientiﬁc) was used to obtain the FTIR spectra. X-
ray diﬀraction (XRD) was carried out to conﬁrm the order of the
mesopores from the nanoparticles in a Philips X-Pert MPD
diﬀractometer equipped with Cu Kα radiation. N2 adsorption was
carried out to obtain surface area and pore size values. Micromeritics
ASAP 2010 instrument was used; surface area was obtained by
applying the BET method to the isotherm, and the pore size
distribution was determined by the BJH method from the desorption
branch of the isotherm. The mesopore diameter was determined from
the maximum of the pore size distribution curve. Fluorescence
spectrometry was used to determine cargo release by means of a
Biotek Synergy 4 device. Fluorescence microscopy was used to verify
the colocalization on MSNs and siRNA constructs. It was performed
with an Evos FL Cell Imaging System equipped with three LED light
cubes (lEX, nanometers; lEM, nanometers): DAPY (357/44; 447/
60), GFP (470/22; 525/50), and RFP (531/40; 593/40) from AMG
(Advance Microscopy Group).
Optimization of siGLO Binding to MSNs@PEI Nanoparticles.
The transfection conditions and the release eﬃciency were optimized
using a siRNA-analog called siGLO Green Transfection Indicator
(Abs/Em max 494/520 nm). The siRNA binding capability of
MSNs@PEI was determined by agarose gel retardation assay.
Diﬀerent amounts of MSNs@PEI ranging from 0.8 to 6.4 μg were
mixed with 0.1 μg of siGLO in aqueous solution to obtain particle-to-
nucleic acid ratios (N/P) of 8−64. N/P is a mass ratio in which N
and P, respectively, correspond to the moles of positive (nitrogen
(MSNs@PEI)) and negative (phosphonate (siGLO)) charges. Free
siGLO was used as control. A total of 20 μL of MSNs@PEI and
siGLO complex solution were mixed with 5 μL of loading buﬀer and
electrophoresed in a 2% agarose gel containing 0.5 μg/mL of GelRed
(Nucleic Acid Gel Stain) at 80 V for 40 min in Tris/Borate/EDTA
(TBE) running buﬀer. Nucleic acid bands were detected by UV light
(254 nm). It is important to mention that only uncomplexed siGLO is
able to migrate to the positive electrode and, therefore, observed on
the gel. Then, when the spot of free siGLO is no longer visible means
that the amount of nanoparticles added had complexed with all the
siGLO present (total binding particle/nucleic acid). The lowest N/P
ratio that complexed all the siGLO is called threshold.41 In 8 and 10
kDa MSN@PEI appears the same threshold, 32, but for 5 kDa PEI,
the threshold was 16.
SiGLO Loading and Release from MSNs@PEI. The ﬁnal
concentration to bind the siGLO in the polymer (N/P ratio of 32)
was achieved adding 165 μL of siGLO (20 μM) to 0.35 mL of a 4
mg/mL solution of MSNs@PEI in PBS 7.4 (10 mM). A 24-transwell
plate was employed to determine the siGLO release. To perform the
assay, 0.1 mL of the nanoparticle dispersion were placed on a
Transwell permeable support (three replications were performed).
The well was ﬁlled with 0.6 mL of PBS pH 7.4 (10 mM), and the
suspension was orbitally stirred at 37 °C at 100 rpm during all the
experiment. At every time point studied, the solution outside the
transwell insert was removed and replaced with fresh PBS. The
amount of cargo released in the solution removed was determined by
ﬂuorescence (absorbance/emission: 494/520 nm).
Cell Cultures. Cell culture tests were performed using MEFs
because they are known to express SOST gene. MEF cells were then
plated at a density of 20 000 cells per square centimeter in 1 mL of
DMEM, respectively, containing 10% of heat-inactivated fetal bovine
serum and 1% penicillin−streptomycin at 37 °C in a humidiﬁed
atmosphere of 5% CO2, and incubated for the speciﬁc time of each
experiment. The tested nanoparticles were placed into each well of
12- or 24-well plates after cell seeding. Some wells without
nanoparticles were seeded as controls.
Cell Viability. MEF viability was determined by addition of
Alamar Blue solution at 10% (v/v) to the cell culture. After 2 h of
contact with diﬀerent concentrations of modiﬁed MSNs (n = 3), the
cells were grown for 48 h in 24 well plates at a density of 104 cells per
square centimeter. Afterward, Alamar Blue solution was added
following the manufacturer’s instructions.55 Fluorescence intensity
was measured using excitation emission wavelengths of 570 and 600
nm, respectively, in a Unicam UV-500 UV−visible spectrophotom-
eter.
Cell MSNs@PEI Uptake by Flow Cytometry, Fluorescence,
and Confocal Laser Scanning Microscopy. MEF cells were
cultured in each well of a 12-well plate and incubated at diﬀerent
times in the absence or presence of the tested FITC-labeled
nanoparticles at a concentration of 50 μg/mL (MSNs, MSNs@PEI,
and MSNs@PEI-siGLO). After 2 h, cells were washed twice with PBS
and incubated at 37 °C with trypsin−EDTA solution for cell
detachment. The reaction was stopped with culture medium after 5
min, and cells were centrifuged at 1000 rpm for 10 min and
suspended in fresh medium. Then, the ﬂuorescence present in the
surface of the cells was quenched with Trypan blue (0.4%) to conﬁrm
the presence of intracellular and, therefore, internalized ﬂuorescent
signal. Flow cytometry measurements were performed at an excitation
wavelength of 488 nm, and green ﬂuorescence was measured at 530
nm (FL1). The trigger was set for the green ﬂuorescence channel
(FL1). The conditions for the data acquisition and analysis were
established using negative and positive controls with the CellQuest
Program of Becton−Dickinson, and these conditions were maintained
during all the experiments. Each experiment was carried out three
times and single representative experiments are displayed. For
statistical signiﬁcance, at least 10 000 cells were analyzed in each
sample in a FACScan machine (Becton, Dickinson and Company)
and the mean of the ﬂuorescence emitted by these single cells was
used.
The cell uptake of MSNs was evaluated using ﬂuorescence and
confocal laser scanning microscopy incubating the cells with
Rhodamine-B-labeled MSNs, MSNs@PEI, and MSNs@PEI-siGLO
for 2 h. Each well was washed with PBS three times to clear the no
internalized nanoparticles and then ﬁxed with 75% ethanol for 10 min.
Cells were permeabilized with 0.5% of Triton X-100 during 5 min.
The nonspeciﬁc background was reduced through the addition of 1%
bovine serum albumin (BSA) to the solution and left for 20 min. The
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nucleus of both types of cells were stained with 4′,6-diamidino-2-
fenilindol (DAPI, ≥ 98%) for 5 min, respectively, and then washed
three times with PBS. The nanoparticles internalized into MEF cells
were evaluated by ﬂuorescence microscopy and performed with an
Evos FL Cell Imaging System and with a confocal laser scanning
microscope Olympus FV1200. The images were prepared for analysis
using 3D Imaris software to project a single 2D image from the
multiple Z sections by using an algorithm that displays the maximum
value of the pixel of each Z slice of 1 μm of depth. The resulting
projection was then converted into an image ﬁle using this software.
The red channel was used for detecting Rhodamine-B-labeled
MSNs@PEI, green channel for siGLO and blue for cell nucleus.
SOST mRNA Expression and siRNA Transfection. MEFs were
seeded in 12-well plates and incubated during 3, 7, 14, and 21 days (n
= 3). Total RNA was isolated from MEF cells by a standard procedure
(Trizol, Invitrogen, Groningen, The Netherlands), and cDNA
synthesis was performed using a high-capacity RNA-to-cDNA kit.
Gene expression was analyzed by real-time PCR using a QuantStudio
5 Real-Time PCR System. Unlabeled mouse-speciﬁc primers for
SOST, Runx2, Alp, and TaqMan MGB probe were used to perform
qRT-PCR assay. The mRNA copy numbers were calculated for each
sample by using the cycle threshold (Ct) value. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) rRNA (a housekeeping gene)
was ampliﬁed in parallel with tested genes. The relative gene
expression was represented by 2−ΔΔCt, where ΔΔCt = ΔCttarget
gene − ΔCtGAPDH.
The eﬃcacy of gene silencing using speciﬁc SOST siRNA on MEFs
in vitro was tested seeding cells in 12-well plates and incubated for 2
weeks. Cells were then transfected with the speciﬁc siRNAs at 0.5 μM
concentration and incubated as required (experiments run for
triplicate). To optimize the experiment, two controls were used: a
negative control siRNA (“non-targeting control”, which targets a site
that is absent in human, mouse, and rat genomes) as well as a positive
control (“GAPD control”, which targets GAPDH, a gene common
between human, mouse, and rat). SiRNA transfection was promoted
using Accell siRNA transfection media. Transfection progressed for 2
h and after that, and cells were lysed with 500 μL of Trizol. Then,
gene expression was analyzed by real-time PCR as described before.
Bar graphs represent expression of SOST mRNA relative to GAPDH.
SOST mRNA Knockdown by MSNs@PEI-siRNA. MSNs@PEI-
siRNA complexes were prepared with the N/P ratios previously
described. First, 15 μL of 20 μM SOST siRNA or negative or positive
control siRNA were added to 70 μg of MSNs@PEI 5kD (N/P ratio =
16) in 600 μL of DMEM. The complexes were added to MEFs cells at
day 14 and exposed for 2 h. Then, the medium was replaced with
fresh medium and cultured for further 48 h. Cells were then lysed
using 500 μL of Trizol, and the SOST, Runx2, and Alp expression
levels were quantiﬁed by real-time PCR as previously described.
Osteostatin Loading and Release. The MSNs were loaded
before PEI coating with osteostatin (OST) by incubating 5 mg of
MSNs in a solution of OST 10−4 M in PBS overnight at 4 °C to
maintain osteostatin stability. Then, the nanoparticles were recovered
by centrifugation and washed with PBS. The loaded nanoparticles
were functionalized with PEI, as previously described. Then, the OST-
loaded MSNs@PEI nanoparticles (OST-MSNs@PEI) were centri-
fuged and washed with PBS.
A 24-transwell plate was employed to determine the OST release.
From a 14 mg/mL dispersion of OST-MSNs@PEI dispersed in PBS
with a pH of 7.4 (10 mM), 0.1 mL was placed on a Transwell
permeable support (3 replications were performed). The well was
ﬁlled with 0.6 mL of PBS pH 7.4 (10 mM), and the suspension was
stirred at 100 rpm at 37 °C during the experiment. At every time
point studied, the solution outside the transwell insert was measured
by ﬂuorescence and replaced again on the plate. The amount of cargo
released was determined by ﬂuorescence at a wavelength of
absorbance/emission of 280/320 nm. It was conﬁrmed by a gel
electrophoresis assay that osteostatin loading process keeps unaﬀected
the binding ability of OST-MSNs@PEI to siGLO.
Osteostatin Delivery in MEF Cells in the Presence and
Absence of siRNA SOST. For the performance of the experiment,
ﬁrst MSNs were loaded with osteostatin as described before;
afterward, they were coated with PEI and bound to siRNA (OST-
MSNs@PEI-siRNA). Then, 15 μL of 20 μM SOST siRNA or
negative or positive control siRNA were added to 70 μg of OST-
MSNs@PEI 5kD (N/P ratio of 16) in 600 μL of DMEM. The
complexes were added to MEFs cells at day 14 and exposed for 2 h.
OST-MSNs@PEI were also used as control. Then, the medium was
replaced with fresh medium and cultured for further 48 h. Cells were
then lysed using 500 μL of Trizol, and the SOST, Runx2, and Alp
expression levels were quantiﬁed by real-time PCR as previously
described.
In Vivo Evaluation. Young mature virgin female C57BL/6J mice
(Charles River) that underwent bilateral OVX or sham operations
(control) of 12 weeks of age were used. They were assigned to 6
groups (n = 5 per group), OVX, MSNs, MSNs@PEI-siCtl, MSNs@
PEI-siRNA, OST-MSNs@PEI, OST-MSNs@PEI-siRNA, and one
more control group with 5 mice. They were stabilized in the Animal
Research Facility at Hospital 12 de Octubre for 2 weeks. All animal
experiments in this study were performed according to approved
protocols. Animals were given free access to water and fed a standard
diet (8.8 g/kg calcium and 5.9 g/kg phosphate) in a room maintained
at 22 °C on 12 h light/12 h dark cycles.
Mice were anesthetized with isoﬂurane, and 50 μL of nanoparticle
dispersion (0.8 mg/mL) was injected in the femur bone marrow by
bilateral oblique incisions that were made over the patellar ligament. A
hole was made through patellar ligament using the needle from the
syringe, and then the dispersion was injected.
After 5 days, mice were euthanized by incubating them with 5%
isoﬂurane in oxygen, and both femurs, the one injected with
nanoparticles and the other one as control, were removed. Bone
samples were crushed under liquid nitrogen. Total RNA was extracted
from these homogenized samples with Trizol following the
manufacturer’s instructions. SOST, Runx2, and Alp expression levels
were quantiﬁed by real-time PCR as previously described.
Dual-Energy X-ray Absorptiometry. The bone mineral density
of femur was measured in anaesthetized control and ovariectomized
mice at the start of the study to conﬁrm decreased bone mass using
PIXImus (GE Lunar Corp., Madison, WI).12
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